Aims
To clarify the clinical characteristics and outcomes of children with SCN5A-mediated disease and to improve their risk stratification.
..

Methods and results
A multicentre, international, retrospective cohort study was conducted in 25 tertiary hospitals in 13 countries between 1990 and 2015. All patients < _16 years of age diagnosed with a genetically confirmed SCN5A mutation were included in the analysis. There was no restriction made based on their clinical diagnosis. A total of 442 children {55.7% boys, 40 .3% probands, median age: 8.0 [interquartile range (IQR) 9.5 ] years} from 350 families were included; 67.9% were asymptomatic at diagnosis. Four main phenotypes were identified: isolated progressive cardiac conduction disorders (25.6%), overlap phenotype (15.6%), isolated long QT syndrome type 3 (10.6%), and isolated Brugada syndrome type 1 (1.8%); 44.3% had a negative electrocardiogram phenotype. During a median follow-up of 5.9 (IQR 5.9 ) years, 272 cardiac events (CEs) occurred in 139 (31.5%) patients. Patients whose mutation localized in the C-terminus had a lower risk. Compound genotype, both gain-and loss-of-function SCN5A mutation, age < _1 year at diagnosis in probands and age < _1 year at diagnosis in non-probands were independent predictors of CE.
.. Conclusion
Introduction
Mutations in the gene (SCN5A) encoding the alpha subunit of the cardiac sodium channel (NaV1.5) cause type 3 long QT syndrome (LQT3), 1 type 1 Brugada syndrome (BrS-1), 2, 3 progressive cardiac conduction disorders (PCCD), 3, 4 atrial standstill and sick sinus syndrome (SSS), 5 familial atrial fibrillation (AF), 6 multifocal ectopic Purkinje-related premature contractions (MEPPC), 7 dilated cardiomyopathy (DCM), 8 and sudden infant death syndrome (SIDS). 9, 10 Some patients with SCN5A mutations are predisposed to sudden cardiac death (SCD), independently of age. A cardiac sodium channelopathy comprises a substantial proportion of aborted cardiac arrest (ACA) in children and adolescents. 11 Cardiac sodium channelopathies are diagnosed in infancy and early childhood following symptoms, sudden death, or family screening. 12, 13 Due to cascade genetic screening, the number of detected asymptomatic children with a SCN5A mutation is increasing. There is a significant variation in management of these asymptomatic SCN5A mutation-positive children amongst paediatric electrophysiologists. 14 This is due to their relative rarity in the paediatric population. Therefore, challenging questions in clinical practice remain unanswered, and risk stratification is inadequate. This study aimed to assess the genotype-phenotype relationship and the risk analysis of cardiac sodium channelopathies in a large cohort of infants and children in order to improve their management.
Methods
Study design
A multicentre, international, retrospective cohort study was conducted in 25 tertiary hospitals in 13 different countries from January 1990 to December 2015. Institutional review board approval was obtained from all participating institutions. All deceased and living patients < _16 years of age diagnosed with a genetically confirmed SCN5A mutation were eligible for the study. There were no restrictions to the clinical diagnoses.
Patients without a baseline electrocardiogram (ECG) were excluded from the analysis.
Clinical investigations
In all patients, demographic data, personal and family history (FH), mode of presentation, ECGs, echocardiography, treatment, and major cardiac events (MCEs) throughout follow-up were ascertained. Electrolyte and metabolic disturbances were excluded through laboratory tests. Study physicians gave their patients information about lifestyle modifications, such as aggressive antipyretic measures, the need for ECG monitoring during fever episodes, and avoidance of appropriate proarrhythmic drugs. Therapeutic management of the patients was based on the clinical judgement of the referring cardiologist. In case of device implantation, pacemaker (PM) type and mode of pacing, or implantable cardioverterdefibrillator (ICD) type and number of appropriate/inappropriate shocks were noted, as well as other device-related complications.
Genetic analysis
Mutation analysis of the SCN5A gene followed standard accepted protocols for genetic testing. Amino acid numbering was made according to transcription variant 1 of SCN5A (http://www.ncbi.nlm.nih.gov/; NM_198056) and the predicted structure reported by Wang et al., 15 according to which the NaV1.5 alpha subunit protein consists of four transmembrane domains, each composed of six segments. The biophysical properties, type, and topological location of SCN5A mutations were determined on the basis of previously published data. 16 : disease-causative mutation databases, localization to highly conserved amino acid residues/key functional domains, co-segregation of the variant with the disease phenotype, evidence of perturbed ion channel function through in vitro functional studies. In case of double SCN5A mutation, patients were considered for risk analysis according to mutation location only if both mutations had the same location.
Statistical analysis
Continuous data were presented as mean ( 
Results
A total of 442 children [246 boys (56%), 178 probands (40%), and median age at diagnosis of 8.0 (IQR 9.5) years] from 350 distinct families were eligible for the study.
Baseline clinical characteristics
Most of the patients (68%) were asymptomatic at diagnosis (Supplementary material online, Figure S1 ). The four 'major' ECG phenotypes at baseline were isolated PCCD (26%), overlap phenotype (16%), isolated LQT3 (11%), and isolated BrS1 (2%); 196 (44%) patients had a negative ECG phenotype at baseline ( Figure 1 ). Clinical characteristics of each patients' group are detailed in Supplementary material online. All groups had similar gender distribution (P = 0.13) and median age at diagnosis (P = 0.32). The proportion of probands differed among groups (P = 0.02). Table S1 ).
Clinical outcomes
Overall there were 272 MCEs in 139 (31%) patients during a median follow-up period of 5.9 years (IQR 5.9). Fifty (11%) patients had recurrent MCEs on treatment. Of the 77 (17%) ICD-implanted patients, 100 appropriate shocks were delivered in 28 (36%) patients during a median follow-up period of 3.3 years (Supplementary material online, Table S2 ). Inappropriate ICD shocks occurred in nine patients (12%; T wave oversensing in seven patients, AF in one, and lead fracture in one). The four 'major' ECG phenotypes at baseline developed as follows:
Isolated progressive cardiac conduction disorder patients At a median follow-up of 5.7 (0.0-35.7) years, 26/113 (23%) patients kept an isolated PCCD phenotype; 13/113 (11%) had received PM implantation at a median age of 5.42 (0.06-15.58) years; 85% of PCCD patients had their first PM insertion by the age of 11; permanent PM were implanted for symptomatic bradycardia in 7/13 patients (syncope in 5, exercise-induced dyspnoea in 2), whilst the indications were prophylactic in 6/13 patients, including a mean daytime heart rate <50 b.p.m. in 4 children >1 year of age and ventricular pauses longer than 3 RR intervals in 2; 38/113 (34%) experienced > _1 MCE, the first of which being cardiac arrest [18% including 3 documented ventricular tachycardia (VT), 1 polymorphic VT with torsades de pointes (TdP), and 1 ventricular fibrillation (VF)], SIDS (2%), or syncope (14%). At the time of their event, PCCD patients presented with the association of an AVB and right bundle branch block (RBBB) (17/38, 45%), an isolated first-degree AVB (13/38, 34%), an isolated complete RBBB (4/38, 10.5%) or a trifascicular block (4/38, 10.5%). Two patients died (one during infancy, one SCD) and one required heart transplantation for intractable arrhythmias; although none of them underwent a sodium-channel blocker challenge, all three patients maintained an isolated cardiac conduction disorders phenotype throughout follow-up.
Overlap phenotype patients After 5.7 (0.0-45.7) years, 34/69 (50%) patients had pharmacological treatment (beta-blocker: 39%, sodium channel blocker: 22% according to the combination of phenotypes, see Supplementary material online, Table S3 ); PM or ICD had been implanted in 10/69 (14%) and 17/69 (25%) respectively. At least one MCE occurred in 31/69 patients (45%; 1 recurrence in 6 patients, 2 recurrences in 1 patient, and > _2 recurrences in 5 patients). Three patients died from SCD and one required extracorporeal membrane oxygenation support and was then transplanted for intractable arrhythmias. 
Isolated type 3 long QT syndrome patients
At a median follow-up of 5.9 (0.0-26.5) years, 32/47 (68%) patients received a beta-blocker, coprescribed with a sodium channel blocker in 10 (21%), 3 (6%) had undergone left cardiac sympathetic denervation and PM and ICD implantation occurred in 3 (6%) and 11 (23%), respectively.
Major cardiac event occurred in 25 patients [53%, 5/25 (11%) < _1 year of age, 1/25 (4%) on beta-blocker at the time of the event] (Supplementary material online, Table S4 ). The first MCE was a SCD (2/47: 4%, including 1 during infancy), an ACA (19%) or a syncope (30%). Nine patients experienced more than one MCE. At the time of the first recurrent event, 7/9 patients were receiving beta-blocker therapy (Supplementary material online, Table S5 ); three patients experienced several recurrences under a coprescription of betablocker and mexiletine. Seven ICD shocks (6 appropriate, 1 inappropriate) were delivered in 3/11 (27%) implanted patients. Six (13%) patients died throughout follow-up, three of them had experienced a MCE in the first year of life.
Isolated type 1 Brugada syndrome patients After 8.1 (1.8-15.7) years, 3/8 (37%) symptomatic BrS1 patients had an ICD (2.8, 11.5, and 18.8 years at implantation). They had presented with syncope (2 patients) or documented VT. One of them experienced a fever-associated VF-induced appropriate ICD shock at 13 years whilst under treatment. No death occurred. The five remaining patients were asymptomatic and left untreated.
Negative electrocardiogram phenotype patients
One hundred and ninety-six patients [44%, 52% boys, 33% probands, median age at diagnosis: 8.8 (IQR 8.7 ) years] had a normal ECG at baseline and underwent genetic screening because of cardiac arrest (7%), syncope (13%), or because of familial screening in asymptomatic patients (80%). A FH of either SCD/ICD implantation or PCCD/ PM implantation was noted in 55% and 15%, respectively.
Of the 196 phenotype-negative patients, 27% developed an ECG phenotype throughout follow-up [5.9 (0.4-26.5 ) years], represented by an isolated PCCD phenotype (13%), an isolated LQT3 (5%), an isolated BrS1 (5%), or an overlap phenotype (4%), whereas 73% remained phenotype-negative. At least one MCE occurred in 40 (20%).
Of the 39 (20%) symptomatic, negative ECG phenotype patients, 26 received a beta-blocker. All but one negative ECG phenotype patients who experienced MCEs during follow-up were already symptomatic at diagnosis. Twelve experienced at least one recurrent MCE at a median delay of 3.9 (9.6) years since the diagnosis [median age of recurrent event: 3.0 (4.3) years]. All but one were treated by beta-blocker therapy at the time of the recurrent MCE; Of these 12 children, 8 kept a negative ECG phenotype at last visit, whereas 4 were further diagnosed with an isolated LQT3 phenotype and, despite additional treatment with mexiletine, experienced further recurrent MCEs leading to left cardiac sympathetic denervation (LCSD) and ICD implantation.
The vast majority (156/157, 99%) of the asymptomatic, negative ECG phenotype children remained asymptomatic throughout follow-up; one patient (0.6%) however became later symptomatic: this was a 5 year-old female patient with a normal ECG at familial screening; she was further diagnosed with an isolated LQT3 on follow-up ECGs at age 13 (QTc 491 ms) and received mexiletine; at age 18, she presented with an electrical storm whilst receiving mexiletine (500 mg morning, 250 mg afternoon, and 500 mg evening), leading to ICD implantation.
Genetic characteristics
The 442 SCN5A genotype-positive children had 185 independent SCN5A variants (Supplementary material online, Table S5 ). Three (0.7%) patients harboured a double heterozygous SCN5A mutation; 9 (2%) had a compound genotype with an additional disease-causing mutation in another gene: KCNQ1 (3 patients), KCNH2 (4 patients), RYR2 (1 patient), or CACNA1C (1 patient). A loss-of-function mutation was found in 178 (40%) patients whereas, 87 (20%) had a gainof-function mutation, 85 (19%) a both gain-and loss-of-function Table S6 ). Most variants were missense pathogenic mutations (64%), whereas 25% were nonmissense pathogenic mutations (truncation mutations: 18%, in-frame mutations: 7%). Topological location of mutations is shown in Supplementary material online, Figure S2 .
Genotype-phenotype correlations Mutation topological location
Patients with a mutation in the C-terminus domain (n = 110) were less frequently probands (P = 0.03), were diagnosed later in life (P = 0.01), were less frequently symptomatic at diagnosis (P = 0.001), had less MCEs (P = 0.0002) and less appropriate ICD shocks (P = 0.03) during follow-up (Supplementary material online, Table S7 and Take home Figure) . No significant difference was found when comparing variants localized in S1-S4 to those localized in S5-S6 in the relevant 241 patients (Supplementary material online, Table S8 ).
Mutation functional effect
Children with a gain-of-function SCN5A mutation mainly presented with a baseline negative ECG phenotype (45%) or isolated LQT3 (26%); those with a loss-of-function mutation presented mainly with isolated PCCD (38%), negative ECG phenotype (27%), or overlap phenotype (19%) at baseline; and those with a both gain-and loss-offunction mainly had negative ECG phenotype (35%), isolated PCCD (22%), isolated LQT3 (12%), or overlap phenotype (14%) (Supplementary material online, Table S9 ). Comparison between groups by looking at the functional effect of the mutation (gain of function, loss of function, or both) demonstrated that gain-offunction mutation carriers were more likely to have a cardiac arrest as first presentation (P < 0.001) and a greater rate of both MCEs during follow-up (P < 0.001) and ICD implantation (P < 0.001).
Mutation type
Non-missense mutation were more frequently identified in case of isolated PCCD (P < 0.006) but less frequently found in case of negative ECG phenotype (P < 0.007) (Supplementary material online, Table S10 ). The following clinical parameters differed according to mutation type: age at diagnosis (P = 0.02), proportion of diagnosis < _1 year (P = 0.02), FH of SCD/ICD (P = 0.03), and FH of PCCD/PM (P = 0.001), as did the following baseline phenotypes: isolated PCCD (P = 0.006) and negative ECG phenotype (P = 0.007) (Supplementary material online, Table S10 ). However, the type of mutation did not change the risk of MCE during follow-up.
Univariate risk analysis
The risk of MCE during follow-up was related to phenotype ( Figure S3 ). Mutation type did not associate with outcomes (P = 0.52) (Supplementary material online, Figure S4) .
Five SCN5A mutations correlated with specific clinical characteristics (Supplementary material online, Table S11 ). For instance, p.Glu1784Lys was associated with a lower risk of CE [P = 0.0002, HR (95% CI) 3.7 (1.8-7.6 )], whereas the presence of p.Val411Met or p.Val1763Met was associated with a higher risk of CE [P < 0.0001, HR (95% CI) 5.1 (2.3-11.4) and P < 0.0001, HR (95% CI): 15.4 (5.4-43.4) , respectively].
Multivariable analysis
A multivariable analysis stratified by baseline phenotype and adjusted on age < _1 year at diagnosis and proband status (interaction, P = 0.0002), genotype (P = 0.03), and mutation functional effect (P = 0.001), showed that age < _1 year at diagnosis in probands [P < 0.0001; HR (95% CI) 35.4 (16.2-77.6 )], compound mutation [P = 0.03; HR (95% CI) 3.7 (1.2-12.0)], age < _1 year at diagnosis in non-probands [P = 0.03; HR (95% CI) 3.2 (1.1-9.1)] and mutation with both gain-and loss-of-function [P = 0.04; HR (95% CI) 0.5 (0.2-0.9)] were independent risk factors for first CE (Supplementary material online, Table S12 ). Quantifiable indication of risk of events in an SCN5A mutation-positive child is presented in Supplementary material online, Figure S5 .
Discussion
This study reports the clinical evaluation and follow-up of the largest paediatric population of SCN5A-mutation-positive individuals reported to date. We presented a highly symptomatic cohort with SCD and ACA in 14%, syncope in 16%, and events during follow-up in 31%. Cardiac conduction disorder was the most prevalent phenotype. Age < _1 year at diagnosis in probands, compound genotype, age < _1 year at diagnosis in non-probands, and both gain-and loss-offunction SCN5A mutation were independent predictors of MCE. We also found that asymptomatic negative ECG phenotype children have a good prognosis, whereas previously symptomatic children with a negative ECG phenotype may undergo recurrent events even under treatment.
Clinical characteristics
The risk for life-threatening arrhythmias was higher in previously symptomatic patients, as previously shown in young BrS 19, 20 and LQT3 patients. 21, 22 We found no gender difference, in phenotype or in the risk for a MCE. Unlike previous adult studies where BrS was predominant in male subjects 23 and life-threatening events were higher among LQT3 men, 24 our results are concordant with previous smaller paediatric reports 19, 25, 26 and the contradiction might be explained by similarities in sex hormones between prepubertal boys and girls. However, the underlying molecular mechanisms are still poorly understood. 27 In our series, more than one-third of isolated PCCD patients experienced MCE, the first of which being cardiac arrest in a high proportion of cases. Phenotypic expression of SCN5A mutations may vary from individual to individual and has an age-dependent onset. 28 Although there is no genotype-based risk stratification for PCCD patients, the occurrence of tachyarrhythmia and SCD was expected to be more frequent in case of loss-of-function SCN5A mutation, as per SCN5A-associated BrS that is a similar disease entity. 29 This was also suggested by familial reports of overlapping phenotypes of BrS1, LQTS, and PCCD 3,12 and the observation that BrS patients with SCN5A mutations exhibit more conduction abnormalities and have a higher risk for MCEs. 30 Our results demonstrate that some isolated PCCD patients are at increased risk of SCD indeed, even at an early age and even if an isolated PCCD phenotype is maintained throughout follow-up, an AVB of any type being an univariate risk factor for CE. Children diagnosed with an AVB of any type should therefore be offered genetic screening; when a SCN5A mutation is diagnosed, ICD therapy should be discussed in this high-risk group in case of additional risk factors that are age < _1 year at diagnosis in probands, compound mutation, age < _1 year at diagnosis in non-probands and SCN5A mutation with both gain-and loss-of-function.
There is also limited data on SCN5A genotype positive children with a negative ECG phenotype. 12, 14 We found that the vast majority of those who are asymptomatic at diagnosis have a good long-term prognosis; however, they need to be followed, as negative ECG phenotype patients may develop a phenotype over time. Negative ECG phenotype children can also present with symptoms; close follow-up and ICD implantation should be considered in symptomatic SCN5A mutation-positive children, even if displaying a negative ECG phenotype, because a substantial proportion of them will experience further recurrent events, even under appropriate treatment.
Correlation between genotype and phenotype
Unlike a previous small report of loss-of-function cardiac sodium channelopathies that indicated that missense pathogenic variants were more common, 25 non-missense pathogenic variants were overrepresented in isolated PCCD in our much larger sample. This is concordant with the role of haploinsufficiency in causing greater impairment of I Na and more severe phenotype leading to PCCD. Phenotype correlation of SCN5A mutation-positive subjects, based on variant location has not been possible before due to small numbers. 31 We found that the N-terminus domain, the DI-DIV region and the C-terminus domain were not over-represented amongst the five main ECG phenotypes. No difference appeared when considering the six segments of the transmembrane domains. However, in a recent case/control study, Kapplinger et al. 17 were able to identify regions of Nav1.5 associated with a high probability of pathogenicity in both BrS and LQT3. In their study, the transmembrane region yielded an overrepresentation of BrS-associated variants, whereas the DIII/DIV interdomain linker and the S3-S5 þ 6 segment of all transmembrane domains hosted an over-representation of LQT3-associated variants. 17 These differences are likely due to ascertainment biases inherent to each study design.
Clinical severity: clinical and genetic predictors
The high incidence of MCEs in our cohort was concordant with a previous small LQT3 paediatric multicentre international study 21 and a recent multicentre series of 391 adult and paediatric LQT3 patients. 22 However, the burden of events was higher than reported by other LQT3 or BrS series in the past. 26, 32, 33 The rate of SCD or ACA in our cohort was 14%, similar to other recent reports on LQT3 patients 21, 22 but significantly higher than that reported in BrS children. 19, 26, 34 This may reflect an over-representation of LQT3 phenotypes in our cohort, as LQT3 patients who experience MCE during the first year of life are at high risk for subsequent MCEs. 32, 35, 36 Indeed, we found that ACA was the first symptom in 23% of the 47 isolated LQT3 children who exhibited a 7% annual rate of CE per year throughout follow-up, although only 1 (4%) was on beta-blocker at the time of the first MCE. Moreover, the two SCN5A mutations associated with an increased risk of MCEs in our series, namely p.Val411Met and p.Val1763Met were both gain-offunction mutations. SCN5A mutations localizing to the transmembrane regions or the N-terminus were associated with a higher risk for CE compared to the C-terminus. This is an important finding that may help geneticists and physicians counselling young affected individuals and their families.
It is recognized that double SCN5A mutation carriers have a more severe phenotype with longer QTc intervals, a younger age at diagnosis, and more CEs despite therapy. 33 Schwartz et al. 36 first raised the issue of different response of LQT3 patients to beta-blockers and/or LCSD between infants with MCEs in the first year of life and those presenting later. This concept was then confirmed by data from the International LQTS Registry showing that patients with an ACA during their first year of life had a very high risk for subsequent ACA or SCD during their next 10 years
